SCHEMBL6523634

SCHEMBL6523634

Cc1c2c(=O)n(CCCNC(=O)OC(C)(C)C)c3ccc(C#CCN(C)C)cc3c2nn1C1CCCCO1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ATR Q13535 4/20 0.41
CNR2 P34972 1/20 0.36
DYRK1A Q13627 1/20 0.34
PLK1 P53350 4/20 0.34
GABRA1 P14867 1/20 0.32
GABRA5 P31644 1/20 0.32
STING1 Q86WV6 1/20 0.32
FNTA P49354 2/20 0.31
FNTB P49356 2/20 0.31
PGGT1B P53609 2/20 0.31
KCNH2 Q12809 1/20 0.31
KRAS P01116 1/20 0.31
BRD4 O60885 3/20 0.31
ATRIP Q8WXE1 1/20 0.31
OPRM1 P35372 1/20 0.31
OPRD1 P41143 1/20 0.31
OPRK1 P41145 1/20 0.31
OGFRL1 Q5TC84 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6515574 0.93 ATR (0.41) ATRCNR2DYRK1APLK1STING1
SCHEMBL6521383 0.91 ATR (0.41) ATRCNR2DYRK1APLK1GABRA1
SCHEMBL6511320 0.89 ATR (0.42) ATRCNR2DYRK1APLK1FNTA
SCHEMBL6512999 0.89 ATR (0.42) ATRCNR2DYRK1APLK1STING1
SCHEMBL6521933 0.89 ATR (0.39) ATRCNR2DYRK1APLK1STING1
SCHEMBL6511027 0.86 ATR (0.42) ATRCNR2DYRK1APLK1BRD4
SCHEMBL6521803 0.86 PLK1 (0.44) ATRCNR2DYRK1APLK1BRD4
SCHEMBL6508889 0.86 ATR (0.42) ATRCNR2DYRK1APLK1STING1
SCHEMBL6511907 0.86 ATR (0.42) ATRCNR2DYRK1APLK1STING1
SCHEMBL6512647 0.86 CNR2 (0.45) ATRCNR2DYRK1APLK1STING1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 ATR 717/4885CNR2 3139/4885DYRK1A 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.